🇺🇸 FDA
Patent

US 12097219

Single-domain antibodies against CLL1 and constructs thereof

granted A61KA61K2039/505A61K2239/29

Quick answer

US patent 12097219 (Single-domain antibodies against CLL1 and constructs thereof) held by Legend Biotech Ireland Limited expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Legend Biotech Ireland Limited
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K2239/29, A61K2239/31, A61K2239/38